Objective-To investigate the effect of intravenous magnesium on mortality in suspected acute myocardial infarction.
Introduction
The relevance of magnesium to both the incidence and the management of ischaemic heart disease is not well understood. Geographical comparisons of entire regions indicate that death rates from ischaemic heart disease tend to be higher where magnesium concentrations in soil and water are low,' and case-control studies indicate that magnesium concentrations tend to be lower, and calcium concentrations higher, in those who die of ischaemic heart disease than in those who die of other causes. 2 Several actions of the magnesium ion could contribute towards some cardioprotective effects.3 Low concentrations of magnesium in laboratory animals seem to potentiate catecholamine induced myocardial necrosis. 4 This may be partly due to the increased coronary artery tone and the increased response to vascoconstrictors (such as angiotensin, serotonin, noradrenaline, and potassium) that is associated with reduced extracellular magnesium concentrations. 5 Early after the onset of myocardial ischaemia, infusion of magnesium might limit the progression ofischaemic to infarcted myocardium and reduce the risk of arrhythmias being induced by raised local concentrations of catecholamines. Increasing serum magnesium concentrations might also limit damage by inhibiting calcium influx into myocardial cells67 or by reducing peripheral resistance, or both. 8 The antiplatelet effects of magnesium9 may also have a role in preventing propagation of coronary artery thrombus and reocclusion of the infarct related coronary artery after spontaneous or fibrinolytic induced recanalisation. It is not clear, however, that platelet function would be further inhibited by magnesium in the presence of aspirin, which is now routinely used in acute myocardial infarction.'0 Magnesium has been shown to limit infarct size in dogs," and infusions of magnesium have also been shown in animal studies to increase the threshold for electrical excitation of myocardial cells,'2 thereby reducing the likelihood that an injury current will create an abnormal focus of excitation near the ischaemic or infarcted tissue. Patients with low magnesium concentrations who have acute myocardial infarction or congestive heart failure more commonly have ventricular arrhythmias,'3 '4 and magnesium seems to be effective in the treatment of torsades de pointes'5 16 and of some arrhythmias that are refractory to conventional antiarrhythmic treatment.'7 Magnesium infusions in acute myocardial infarction have therefore been suggested to prevent serious arrhythmias during the day or two after infarction, when serum magnesium concentrations tend to fall'8 and patients are at a particular risk of ventricular fibrillation.
The need for properly randomised evidence on whether arrhythmias and related mortality can be reduced by magnesium has been reinforced by recent doubts about the safety of some other antiarrhythmic drugs. In some countries (including the United States'9 but not Britain'°) prophylactic lignocaine was commonly used in acute myocardial infarction to prevent ventricular arrhythmias. Recently, however, two independent overviews of the randomised trials involving over 9000 patients have indicated that prophylactic lignocaine may be associated with an increase in total mortality.202' These concerns have been reinforced by the results of the cardiac arrhythmia suppression trial,22 indicating increased mortality with the use of encainide and flecainide in patients with previous myocardial infarction. In addition, an overview of the trials of other class I antiarrhythmic agents shows no benefit when used routinely after myocardial infarction. 23 so that intention to treat analysis could be conducted. 6 
STATISTICAL METHODS
The statistical methods used to analyse the results from these trials have been described previously3' 3X and a detailed description of the relation between medical common sense and the principles and practice of trial overviews may be found in the recent report of the Early Breast Cancer Trialists' Collaborative Group. The fundamental principle is that patients allocated to active treatment in one trial should be compared directly only with those allocated to control in the same trial and not with patients in any other trial. For each trial the number of events observed (0) in the treated group is contrasted with the number that would have been expected (E) if treatment had no effect. If treatment was beneficial the observed minus expected value would tend to be negative (and approximately equal to half the number of deaths prevented by treatment38). Although in any one trial this favourable tendency might be obscured by chance, it should stand out more clearly when the grand total of all the values from the individual trials is examined.
Formal statistical tests of whether treatment is without effect require calculation of z, the number of standard deviations by which the grand total of the observed minus expected values differs from zero and comparison of z with tables of the normal distribution (for example, z=-1 96 suggests a two sided p value of about 0 05 in favour of treatment).
Assessment of treatment effects from the combined data assumes that information is available from all, or from an unbiased sample of all, randomised trials, without important bias due to the unavailability of data from unpromising trials or from patients withdrawn after randomisation. It does not, however, assume that the real effects of treatments are the same size in different trials, but merely that any real effects will tend to be in the same direction. An estimate of the "ctypical" ratio of the odds of dying among patients allocated magnesium with that among controls is given by the formula e(t°-E)/v) with an approximate 95% confidence interval estimated by the formula e((O-E)/'+ 1-96/SD), where V is the variance and SD the square root of V."8 Odds ratios less than 1 0 indicate protection.
Tests for heterogeneity of treatment effects between trials can be performed, but in practice such heterogeneity tests are of limited value, partly because they are so insensitive to any real differences that may exist but chiefly because some heterogeneity will almost or enzyme changes occurring Data on longer term mortality are available from we obtained follow up data, at only two studies. One year mortality in the study by -4% of all randomised patients Rasmussen et al was 20% in the magnesium group r or not infarction was con-compared with 32% in the placebo group (p<0-02).2728 ly unbiased intention to treat In that study the difference in mortality developed All studies excluded patients during the first month (7% v 17%, p<0-01), with little ricular block. Additionally, in further divergence during the remainder of the first vith elevated serum creatinine year (15% v 18%; NS). In the other study that provides ision (systolic blood pressure data on deaths after discharge no difference in morn Hg), severe cardiac failure, tality was observed either early or late, with 22 deaths e >70 years were excluded. In among patients allocated magnesium and 24 among thê , such exclusions were not controls after a median follow up of about 8 months.3" 32 considered necessary.
Magnesium sulphate was infused in five studies and magnesium chloride in the remaining two studies (table II) . The total dose infused varied between 30 mmol and about 90 mmol of magnesium dissolved in as little as 100 ml and as much as 2000 ml of isotonic saline or 5% glucose, with dosage dependent on body weight in one study24l26 and fixed in the other six. The duration of the infusions also varied, ranging from 24 to 48 hours, with 20 minute bolus injections given on three successive days instead of an infusion in one study.3" All of the studies were placebo controlled.
Six of the seven trials provided some information on serum magnesium concentrations (table II) . The mean pretreatment concentrations were 0 8-0 9 mmol/l and were similar among patients allocated magnesium and those allocated placebo. After randomisation the mean serum concentrations differed by about 0-5 (range 0 2 to 0-7) mmol/l between treatment and control groups. This difference was largely or wholly due to an increase in serum magnesium in the treatment group, as there was little change among thie controls.
OVERALL EFFECT ON MORTALITY
In general, data on mortality were available for almost all randomised patients until they were discharged from hospital. In one study, 29 (table IV) . Ventricular arrhythmias were less common in the magnesium group than in the control group in six of the seven studies, and the difference was significant in two. When all the available information on serious arrhythmias was considered together, there was a significantly lower incidence (p<0001) among patients allocated magnesium. The definitions of serious arrhythmias differed among the trials, so some potential for bias exists in the assessment of the effects of magnesium as the type of arrhythmia chosen for emphasis in the trial might have been influenced by the observed results. Limitation of infarct size was studied systematically in only one study,2426 where infarct size (as estimated by concentrations of the MB isomer of creatine kinase) was smaller, though not significantly so, in the magnesium group. Another study found that fewer patients allocated magnesium had infarction confirmed,27"2 but this difference was only marginally significant (p=0O04) and was not supported by the available data from other trials.
Possible serious adverse effects of magnesium, such as conduction disturbances or heart failure, were not always systematically looked for. Data on the development of heart failure were available from five of the seven trials (table V) . However, the definitions used in the trials varied and the numbers of events were small. Although there were no apparent increases (or decreases) among patients allocated magnesium compared with controls, the data are too limited and too incomplete to do more than suggest that magnesium is not associated with any large excesses. Intravenous magnesium produced flushing in some patients,"0 and hypotension was reported,0 but these effects rarely (if ever) required discontinuation of the magnesium infusion.
Discussion
This overview of seven randomised controlled trials of intravenous magnesium in 1301 patients with suspected acute myocardial infarction indicates that, in patients at relatively high risk, treatment reduces mortality during the first few weeks by between one third and two thirds. If real, this is a substantial benefit as intravenous magnesium is likely to be suitable for almost all patients with suspected myocardial infarction, the drug costs are small, there are few contraindications, and serious side effects are rare. Magnesium could be used widely not only in developed countries but in countries with limited medical resources. Even if magnesium infusions could reduce mortality by only one quarter (that is, somewhat less than is suggested even by the lower limit of the 95% confidence interval for this overview) this would be of considerable public health importance worldwide, avoiding tens of thousands of deaths annually.
The general judgment that underlies this approach to the trials of intravenous magnesium is that, although different infusion regimens or different recognisable categories of patient in these trials may have different sized risk reductions, it is less likely that the direction of any effects will be different. This means that an overview of their findings makes good medical sense. (It also makes good statistical sense as biases due to selective emphasis on particular studies need to be avoided.) Even collectively, the total number of deaths available for inclusion in the overview was small (25 Our study provides strong evidence that intravenous magnesium may have a beneficial effect on mortality. The mortality results of most of the seven small trials, included in the overview are not separately persuasive although the results on arrythmias are more conclusive. [27] [28] [29] [30] [31] [32] [33] [34] In the absence of data from large trials of intravenous magnesium, however, it may be most prudent to be guided by our overall results rather than by undue emphasis on any of the small studies. Larger trials are being conducted (the second Leicester intravenous magnesium intervention trial: LIMIT-24°) and planned (ISIS-4), and these should help to determine the safety and efficacy of adding intravenous magnesium to current regimens including other effective treatments such as intravenous 13 
